FMR1 and fragile X syndrome: Indeed, the FXS research field actively seeks new treatments and biomarkers to evaluate their efficiency (Castagnola et al., 2017; Maurin et al., 2018b) and, to date, the main cellular biomarker of cultured Fmr1-KO neurons is represented by their abnormal dendritic spine morphology, whose analysis requires exquisite expertise (Khayachi et al., 2018).